Company profile
Plus Therapeutics, Inc.
NASDAQ: CNSY · Healthcare · Medical - Pharmaceuticals
#700 of 1,418 Healthcare companies by revenue32nd-percentile growth
EA Score
30DFH 25DQ —GM 45SS 32
v0.1 · 45/100 weight · provisional
↑ 3-yr revenue growth, disclosure history · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$4.2M
Rev growth YoY (TTM)
-21.0%
Net income (FY)
-$22.4M
Employees
28
as of 2026-08-23
Market cap
$24.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.2M$5.2M2025
Net income-$22.4M-$22.4M2025
Operating income-$15.3M-$15.3M2025
Total assets$16.3M$16.3M2025
Liabilities$12.3M$12.3M2025
Equity$4.0M$4.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Plus Therapeutics, Inc.’s revenue?
Plus Therapeutics, Inc. booked $5.2M in FY2025 revenue, contracting 10% year over year — slower than 68% of Healthcare companies we track, at a -429.4% net margin.
Peers · Healthcare
Wildflower Brands Inc.——Biomerica, Inc.47DTargeted Medical Pharma, Inc.——Plus Therapeutics, Inc.38DZeo ScientifiX, Inc.43DRadiko Holdings Corp——Neighbors
Harris →Key facts
CEOMarc H. Hedrick
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersHouston, TX
ExchangeNASDAQ: CNSY
Employees28
IPO date2026-08-03
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.